We studied the relation between the occurrence of adverse reactions to trimethoprim-sulfamethoxazole (TMP-SMZ) prophylaxis and the subsequent course of human immunodeficiency virus (HIV) infection in a cohort of homosexual men. Adverse reactions to TMP-SMZ were associated with a more rapid progression to AIDS (P < .001) and death (P < .001) and with a more rapid decline in CD4 ' cell counts (P = .001). The median time to progression to AIDS was 14.9 months in subjects with adverse reactions to TMP-SMZ and 32.5 months in those without adverse reactions. After exclusion of Pneumocystis carinii pneumonia (PCP) and toxoplasmosis from the case definition of AIDS, the differences in the rate of progression to AIDS between subjects with and without adverse reactions to TMP-SMZ were still highly significant (P = .004). A low CD4+ cell count at baseline and the use of antiretroviral agents before the start of prophylaxis were predictors of adverse reactions to TMP-SMZ but did not account for the difference in progression to AIDS between subjects with and without adverse reactions to TMP-SMZ. In a univariate analysis, the relative hazard of adverse reactions to TMP-SMZ for progression to AIDS was 2.54 (95 % confidence interval [Cl], 1.50-4.28); in a multivariate analysis, it was 2.21 (95% Cl, 1.29-3.81) . The relative hazards of adverse reactions to TMP-SMZ for progression to AIDS with the exclusion of PCP and toxoplasmosis, CD4+ cell counts of <50/mm3, and death were 2.16 (95% Cl, 1.25-3.72), 2.37 (95%  Cl, 1.36-4.12), and 3.21 (95% Cl, 1.80-5.72) , respectively. It is unclear whether adverse reactions to TMP-SMZ induce or merely predict progression of HIV disease.
Trimethoprim-sulfamethoxazole (TMP-SMZ) is highly ef-aerosolized pentamidine and oral dapsone, are less effective as fective as treatment and prophylaxis for initial and recurrent prophylaxis for P. carinii infections and toxoplasmosis [7, 8] . episodes of Pneumocystis carinii pneumonia (PCP) [1] [2] [3] . In addition to its efficacy in preventing PCP, TMP-SMZ also protects against toxoplasmosis and several bacterial infections [3] [4] [5] . Although TMP-SMZ is the preferred drug for prophy laxis for PCP, about one-quarter of HIV type 1 (HIV-1 )infected individuals experience adverse reactions that occur mostly within the first month of treatment [61. The alternatives,
We studied the relation between the occurrence of adverse reactions to TMP-SMZ prophylaxis and the subsequent course of HI V infection in a cohort of homosexual men. We found a relatively large difference in survival from the start of PCP prophylaxis to death between HIV-1-infected patients without adverse reactions to TMP-SMZ and those with adverse reac tions to TMP-SMZ. Patients with adverse reactions to TMP-SMZ subsequently had a more rapid progression of HIV infection that could only partly be explained by an increased incidence of PCP or toxoplasmosis.
receiving TMP-SMZ as primary prophylaxis for PCP. The cen-AIDS, CD4 ' cell counts of <50/m nv\ and death were evaluated by using Kaplan-Meier survival methods and logrank stati sties. Differences in progression to AIDS might reflect differences soring date of our study was 31 August 1995. PCP prophylaxis. Since February 1990, asymptomatic HIV-1-infected subjects were advised to start primary prophy laxis for PCP when they had two consecutive CD4+ cell counts in the efficacy of prophylaxis with TMP-SMZ vs. aerosolized of <200/mnr\ In February 1991, the criterion for starting pro-pentamidine. Therefore, the above-mentioned analysis was rephylaxis was changed: asymptomatic H IV -1-seropositive sub-peated with (1) the exclusion of PCP and toxoplasmosis jects were advised to start PCP prophylaxis when they had one the case definition of AIDS and the use of a subsequent AIDS-CD4+ cell count of < 2 00/mm3. defining condition instead and (2) the exclusion of PCP and TMP-SMZ was prescribed as PCP prophylaxis for all pa-toxoplasmosis as primary AIDS-defining events entii tients except three with a history o f adverse reactions to the degree of immunodeficiency, the criterion for TMP-SMZ and seven who participated in an early study of the phylaxis, the dose of TMP-SMZ, and concomitant antiretroviral efficacy of zidovudine, in which only aerosolized pentamidine therapy might be associated with the risk for AIDS and was allowed as PCP prophylaxis [10] ; these 10 subjects were we evaluated the effect of adverse reactions to TMP-SMZ by not included in our study. The initial dose of TMP-SMZ was 960 mg once daily. In August 1991, the TMP-SMZ dose was changed to 480 mg, following a randomized trial that showed that the lower dose had an equal clinical efficacy but fewer side effects [2] . Prophylaxis for all subjects who had to stop taking TMP-SMZ because of adverse reactions was changed to aerosolized pentamidine (300 mg once every 4 weeks).
Comedication. The administration of drugs that might in-means of Cox regression adjustments for these factors.
Results
Between February 1990 and September 1995, 112 AIDSfree HIV-1-infected men (of whom 84 were HIV-seropositive at entry in the cohort and 28 seroconverted to HIV during fluence the metabolism of TMP-SMZ and those that were used follow-up) started receiving TMP-SMZ as primary prophylaxis between the start of TMP-SMZ prophylaxis and the occurrence of adverse events was noted.
Definitions. Adverse reactions to TMP-SMZ were defined as follows: fever (temperature o f >38.5°C), skin rash, and/or gastrointestinal symptoms occurring within 2 months for PCP. All patients except one were Caucasian. TMP-SMZ prophylaxis was stopped permanently for 33 (29%) of the men because of adverse reactions. Fever and/or skin rash occurred in 31 patients (fever and skin rash,'21; fever only, 5; skin rash only, 5); eight of these 31 patients also had gastrointestinal after starting prophylaxis; an event that resolved when symptoms. Two of 33 subjects stopped TMP-SMZ prophylaxis TMP-SMZ treatment was stopped; and the permanent discon-because of gastrointestinal symptoms without fever or skin tinuation of TMP-SMZ treatment. AIDS was defined according to the 1987 revised case definition o f the Centers for Disease Adverse reactions to -SMZ occurred at a later stane of Control and Prevention [11] .
Laboratory methods. Peripheral blood mononuclear cells were isolated from heparinized venous blood by using density gradient centrifugation in Ficoll-Hypaque solution (Phar macia, Piscataway, NJ). Lymphocyte immunophenotyping was determined by flow cytometry. T cell reactivity was mea sured by stimulating cells with CD3 monoclonal antibody (Central Laboratory of the Red Cross Blood Transfusion Ser vice, Amsterdam) and is expressed in counts per minute (nor mal T cell reactivity based on the 95% confidence limit, HIV infection in the group receiving 480 mg than in the group receiving 960 mg (median of 19 days [range, 7 -60 vs. median of 15 days [range, 5 -4 6 ], respectively). Only one of of TMP-SMZ prophylaxis; none of the patients were receiving fluconazole, rifampin, or eimetidine therapy concomitantly. occurrence or absence of adverse reactions to TMP-SMZ cannot be associated with the influence of these P-450 zs on TMP-SMZ. It is 5*1,100 counts per minute) [12] . To detect the presence of to drugs other than TMP-SMZ, since none of syncytium-inducing (SI) HIV-1 variants, which are associ-started receiving therapy with other drugs between the start of ated with a more rapid decline in CD4+ cell count and a more rapid disease progression [13], peripheral blood mononuclear cells were cocultivated with MT-2 cells [14] . graphic data and laboratory markers for the occurrence of ad-(table 1 ). A relatively low CD4 verse reactions to TMP-SMZ was evaluated by using logistic cell counts of <200/nim^ before the start of TMP-SMZ prophyregression with likelihood ratio tests (P < .05) in backward laxis were found to be predictors for the development of adand forward selection procedures. Differences in disease pro gression between men with and men without adverse reactions to TMP-SMZ from the start of TMP-SMZ prophylaxis to NOTE, epm = counts per minute; SI = syncytium-inducing; TMP-SMZ = trirnethoprim-sulfamethoxazole, ORs express a protective cfleet for adverse reactions to TMP-SMZ per elevations of 100/mm'1 in CD41 cell counts and elevations of 1,000 cpm in T cell reactivity. ORs express an increased risk for adverse reactions to TMP-SMZ per declines of 100/mm5 in CD4+ cell counts in the year before the start of TMP-SMZ prophylaxis, for repeated CD41 cell counts of <200/mm\ for the presence of SI virus variants, for a high does of TMP-SMZ (960 mg), and for the use of antiretroviral agents before the start of TMP-SMZ prophylaxis.
A high dose of TMP-SMZ and the use of antiretroviral agents treated with aerosolized pentamidine and in another patient (zidovudine and, for a few patients, zidovudine combined with without adverse reactions to TMP another nucleoside analogue) before the start of TMP-SMZ prophylaxis were associated with the occurrence of adverse reactions, but these associations were not statistically signifi cant. In a multivariate analysis, after correction for CD4+ cell counts, the odds ratio for the use of antiretroviral agents before the start of prophylaxis increased to 2.72 (P .03). AIDS developed in 26 (79%) of 33 patients with adverse reactions and in 37 (47%) of 79 patients without reactions to TMP-SMZ (table 2) . PCP occurred in one patient who was T able 2. The first AIDS-defining disease and the number of deaths in I-IIV-infected patients with and without adverse reactions to TMP-SMZ. without adverse reactions to TMP-SMZ who had not taken prophylaxis for several months. Toxoplasmosis of the brain occurred as the first AIDS-defining event in eight (24%) of 33 patients with adverse reactions to TMP-SMZ but in none of the patients without adverse reactions (P < .001).
The association of adverse reactions to TMP-SMZ with pro gression of HIV disease from the start of TMP-SMZ prophy laxis (baseline) was evaluated by means o f Kaplan-Meier sur vival analysis. Adverse reactions to TMP-SMZ were associated with faster progression to AIDS, death, and C D 41 counts of < 50/mm3 (figure 1). The median time from the start of prophylaxis to progression to AIDS was 14.9 months for sub jects with adverse reactions to TMP-SMZ and 32.5 months for patients without adverse reactions. The median time from the start of TMP-SMZ prophylaxis to death was 28.3 months in subjects with adverse reactions and 51.9 without adverse reactions.
s in patients
When PCP and toxoplasmosis were excluded from the case definition of AIDS and a subsequent AIDS-defining condition was used instead, the differences in the rate of progression to AIDS were still highly significant (figure 1). In addition, when patients for whom PCP or toxoplasmosis was the AIDS-defin ing event were excluded from the analysis, the differences remained significant (P -.004). Thus, the difference in pro gression to AIDS in patients with and without adverse reactions to TMP-SMZ is not merely a reflection of the prophylactic effect of this therapy on toxoplasmosis.
Cox regression (proportional hazards analysis) was used to determine whether the differences in progression to AIDS between patients without reactions to TMP-SMZ could be explained by differences at the start of prophylaxis (table 3) . The relative hazard of adverse reactions to TMP-SMZ for progression to AIDS was 2.54 (95% Cl, 1.50-4.28). In a univariate analysis, a low C D 41 cell count at the start of TMP-SMZ prophylaxis, repeated CD4 ' o f <200/mm3 before the start of prophylaxis, and a low T cell reactivity were also significantly associated with progression to AIDS (table 3) . Biological virus phenotype (S1/NS1), the dose of TMP-SMZ, and the use of antiretroviral agents before the start of prophylaxis were not statistically associated with < 50/mm3 (RM, 2.37; 95% Cl, 1.36.4.12), and death (RH, 3.21; 95% CI. 1. *.*(■ *03 5.72).
Discussion

reveals a between the occur rence of adverse reactions to TMP-SMZ and the course of HIV
•se reactions to a more rapid progression to AIDS and death and with a more progression to AIDS. The relative hazard of adverse reactions rapid decline in CD4 counts. In agreement with ings o f other investigators [3, 5, 15] , we decrease in the incidence of event, in patients treate the difference in the rate of xi a s to TMP-SMZ was not substantially altered by controlling lor CD4 * cell counts, repeated CD4+ cell counts of < 200/mm3, and T cell reactivity at baseline (bivariate analysis; table 3 ).
Multivariate analysis demonstrated that adverse reactions to TMP-SMZ, a low CD4+ cell count at baseline, a low T cell reactivity, and the use of antiretroviral agents before the start solized pentamidine could not be explained by this of TMP-SMZ prophylaxis were independently associated with faster progression to AIDS (table 3) . Similar associations with adverse reactions were found in an analysis of progression to Table 3 . Relative hazards for progression to AIDS in HIV-infected dependable predictors of adverse reactions to TMP-SMZ. The men with and without adverse reactions to TMP-SMZ.
incidence of rashes due to TMP-SMZ in HIV-infected individu als with CD4+ cell counts of < 200/mm3 was higher than that in HIV-infected individuals with higher CD4+ cell counts in one study [16] . Similar results have been observed for HIV-1-infected indi viduals treated with amoxicillin/clavulanate [17] . However, in a study of HIV-1 -positive patients with advanced infection who received high dosages of TMP-SMZ (120 mg/[kg • d]) during treatment of PCP [18] , it was found that adverse reactions occurred more often in patients with high CD8 ' or CD4+ cell counts and that adverse reactions could be predicted by a CD4+/CD8+ ratio of >0.10. The latter correlation was not observed by other investigators [19] .
It is not clear whether the discrepancy in the relation between CD4+ cell count and adverse reactions to TMP-SMZ is ex plained by the different degree of immunodeficiency, the large difference in the dose of TMP-SMZ, or the presence of active PCP. An increase in the incidence of adverse reactions to TMP-SMZ in early stage HIV disease and a decrease in the incidence of these reactions in late stage HIV disease might explain this discrepancy.
Use of antiretroviral agents before the start of TMP-SMZ prophylaxis was a predictor of adverse reactions to TMP-SMZ and was also associated with a more rapid progression to AIDS and death. An interaction of zidovudine and TMP-SMZ or a difference in the degree of disease progression that is not re- NOTE. cpm = counts per minute; SI = syncytium-inducing; TMP-SMZ = trimethoprim-sulfamethoxazole. Relative hazards were determined for the presence of adverse reactions to TMP-SMZ per elevations of 100/mm3 in CD4+ cell counts and elevations of 1,000 cpm in T cell reactivity, for repeated CD4+ cell counts of <200/mm\ for the presence of SI virus variants, for a low dose of TMP-SMZ (480 mg), and for the use of antiretroviral agents before the start of TMP-SMZ prophylaxis. fleeted in CD4 cell counts might explain the increased risk of adverse events. The transient effect of zidovudine on CD4+ cell counts and disease progression may have already ended in patients who used antiretroviral agents before (median time, 22.7 months) the start of TMP-SMZ prophylaxis, which might explain their shortened survival [20] .
It is not clear whether adverse reactions to TMP-SMZ merely indicate or also induce progression of HIV disease. A genetic predisposition for the occurrence of adverse reactions as well cell count at baseline, repeated CD4+ cell counts of as for the progression of HIV disease might explain the associa-< 200/m m \ and the use of antiretroviral agents before the start tion. Adverse reactions to TMP-SMZ may be a marker for of PCP prophylaxis were associated with the occurrence of biological processes that affect the progression of HIV disease.
progression to AIDS and death but did not interfere with the association with adverse reactions. Furthermore, a low CD4+ adverse reactions to TMP-SMZ. It is highly unlikely that differences in survival and in de-Oxidative stress is a potent inducer of both viral activation and ''fA damage in infected cells [21, 22] and might be a factor in clines in C D 41 cell counts between patients with and without the progression of HIV disease [23] . Increased levels of oxidized adverse reactions to TMP-SMZ might be due to a direct effect glutathione in CD41 lymphocytes of HIV-infected individuals of TMP-SMZ or aerosolized pentamidine on the progression have recently been reported [24] ; these increased levels indicate of HIV-1 infection. In two prospective trials of increased oxidative stress. Oxidation also generates the unstable TMP-SMZ vs. aerosolized pentamidine as prophylaxis for PCP hydroxylamine metabolite of sulfamethoxazole, and it has been [3, 15] , no significant differences in overall mortality were postulated that this intermediate plays a central role in the developfound, and no differences in declines in CD4+ cell counts were reported. The present study illustrates that differences in survival between treated and untreated individuals that are ment of adverse reactions to TMP-SMZ [25] .
An accelerated progression o f HIV disease could also have been induced by the occurrence of adverse reactions to found in on-treatment analysis of drug efficacy trials may re-TMP-SMZ. The association of fever with skin rash and the fleet a selection of patients rather than a treatment effect. lower incidence of adverse reactions to TMP-SMZ in patients In the present study, a relatively low CD4+ cell count at treated with corticosteroids [18, 26] suggest that inflammatory baseline and repeated CD4+ cell counts of <200/mm3 were cytokines may be involved. Several cytokines can activate HIV replication that might lead to an accelerated progression of HIV-1 disease [27] , Alternatively, immunosuppression might be induced by the formation of sulfamethoxazole hydroxylamine; this metabolite inhibits the activity of natural killer cells [28] and induces a profound suppression of T cell proliferation [29] .
In conclusion, adverse reactions to TMP-SMZ were associ ated with a more rapid progression of HIV-1 infection that could not be explained by the preventive effect of TMP-SMZ and the use of antiretroviral agents before the start of prophy laxis were predictors of adverse reactions to TMP-SMZ but did not account for the differences in survival. Whether adverse reactions to TMP-SMZ induce or merely indicate progression of HIV-1 infection is unclear.
